Eliana Merle
Stock Analyst at Barclays
(3.54)
# 844
Out of 5,154 analysts
107
Total ratings
47.56%
Success rate
6.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Overweight | $923 | $759.86 | +21.47% | 1 | Mar 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $61.12 | +71.79% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $43.07 | +30.02% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.50 | -40.08% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $456.69 | +32.91% | 2 | Feb 17, 2026 | |
| QURE uniQure | Initiates: Equal-Weight | $31 | $14.27 | +117.24% | 5 | Jan 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $35.04 | +68.38% | 2 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $5.41 | +47.87% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $62.82 | +89.43% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $30.55 | +116.04% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $432.83 | +122.72% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.13 | +193.64% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $231 | $140.13 | +64.85% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $240.65 | +42.12% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $8.48 | +289.15% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $65.36 | +22.40% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $20.07 | +19.58% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $320.66 | +64.35% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $52.52 | -35.26% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.54 | +577.97% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $55.41 | -63.91% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $16.71 | -28.19% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.30 | +247.83% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $13.60 | +54.41% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $83.49 | -16.16% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.30 | -4.14% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $98.40 | -27.85% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $101.50 | +29.06% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $24.86 | -79.89% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $42.82 | -57.96% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.80 | +23.60% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.65 | +443.35% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.34 | +11.58% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $32.92 | +307.05% | 3 | Aug 19, 2020 |
Regeneron Pharmaceuticals
Mar 6, 2026
Initiates: Overweight
Price Target: $923
Current: $759.86
Upside: +21.47%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $61.12
Upside: +71.79%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $43.07
Upside: +30.02%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.50
Upside: -40.08%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $456.69
Upside: +32.91%
uniQure
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $31
Current: $14.27
Upside: +117.24%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $35.04
Upside: +68.38%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $5.41
Upside: +47.87%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $62.82
Upside: +89.43%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $30.55
Upside: +116.04%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $432.83
Upside: +122.72%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.13
Upside: +193.64%
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $140.13
Upside: +64.85%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $240.65
Upside: +42.12%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $8.48
Upside: +289.15%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $65.36
Upside: +22.40%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $20.07
Upside: +19.58%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $320.66
Upside: +64.35%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $52.52
Upside: -35.26%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.54
Upside: +577.97%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $55.41
Upside: -63.91%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $16.71
Upside: -28.19%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.30
Upside: +247.83%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $13.60
Upside: +54.41%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $83.49
Upside: -16.16%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.30
Upside: -4.14%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $98.40
Upside: -27.85%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $101.50
Upside: +29.06%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $24.86
Upside: -79.89%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $42.82
Upside: -57.96%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $17.80
Upside: +23.60%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.65
Upside: +443.35%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.34
Upside: +11.58%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $32.92
Upside: +307.05%